# Macupatide and Eloralintide: Lilly's Next Amylin Combination Angle
> Note: PeptIQ is not a medical provider. Macupatide and eloralintide are investigational. Trial registration is not a treatment recommendation. Educational content only.
If you already read the eloralintide beginner's guide, the next search rabbit hole is macupatide — Lilly code LY3532226 — appearing alone or with eloralintide (LY3841136) in obesity / overweight / type 2 diabetes trial records.
This is the stacking archetype for pipeline nerds: not BPC + TB-500, but multi-agent metabolic design inside one sponsor's portfolio.
What Each Code Name Means
| Name | Code | Public framing |
|---|---|---|
| Eloralintide | LY3841136 | Selective amylin receptor agonist; strong Phase 2 monotherapy weight-loss data; Phase 3 ENLIGHTEN program |
| Macupatide | LY3532226 | Investigational metabolic peptide listed in trial records alone or with eloralintide |
Macupatide does not yet have the same public Phase 2 obesity megaphone as eloralintide. That is exactly why an educational page helps: it prevents people from inventing dosing folklore when all they have is a ClinicalTrials.gov row.
Why Lilly Would Pair Them
Lilly's obesity stack already spans:
- Tirzepatide (GIP/GLP-1)
- Retatrutide (GLP-1/GIP/glucagon)
- Orforglipron (oral GLP-1)
- Eloralintide (amylin)
- Combo / add-on experiments (eloralintide ± tirzepatide; macupatide ± eloralintide)
The strategic pattern is clear: own multiple receptors, then test which pairs deepen response for non-responders or residual obesity.
Amylin + a second Lilly metabolic agent is the same idea as Novo's CagriSema — complementary satiety — executed with Lilly's own molecules.
How to Read the Trial Cluster Without Overclaiming
When a registry lists "macupatide and eloralintide alone or in combination":
- Alone arms establish monotherapy signal and tolerability
- Combo arms test whether two mechanisms beat one
- Dose labels may be masked ("Dose 1–4") until publications
- Endpoints will look familiar: percent weight change, glycemic metrics, AEs, discontinuations
Until peer-reviewed dose tables exist for macupatide, do not copy eloralintide's 1–9 mg Phase 2 map onto macupatide.
Tracker Checklist for Combo Pipeline Watchers
Even if you are only following news (not enrolled in a trial), the useful log fields for any future dual-agent metabolic protocol are:
- Agent A dose + Agent B dose (separate columns)
- Which drug changed this week
- GI score attribution (which escalation triggered symptoms)
- Protein / training adherence
- Average weight + waist
- Clinician reason codes for holds
PeptIQ is built for multi-compound timelines — the failure mode in dual protocols is mixing two drugs into one vague "stack note."
FAQ
Q: What is macupatide?
A: An investigational Lilly compound (LY3532226) appearing in clinical trial records for metabolic populations, studied alone or with eloralintide.
Q: Is macupatide approved?
A: No. Treat it as pipeline literacy.
Q: Is the macupatide + eloralintide combo like CagriSema?
A: Conceptually both explore complementary metabolic pathways. They are different molecules and different trial programs — not interchangeable products.
Q: Should I stack research-market "macupatide" with "eloralintide"?
A: No. Unverified dual investigational stacking is a safety and attribution mess. Stay in clinical channels.
Bottom Line
Macupatide + eloralintide is Lilly's amylin-adjacent combination story to watch beside ENLIGHTEN monotherapy. Learn the code names, refuse fake dose charts, and track dual-agent protocols with separate columns when real data arrives.
Download PeptIQ to keep multi-drug metabolic logs clean.
Educational content only. Not medical advice.
